98 related articles for article (PubMed ID: 21839105)
1. Discovery and development of the χ-conopeptide class of analgesic peptides.
Lewis RJ
Toxicon; 2012 Mar; 59(4):524-8. PubMed ID: 21839105
[TBL] [Abstract][Full Text] [Related]
2. chi-Conopeptide pharmacophore development: toward a novel class of norepinephrine transporter inhibitor (Xen2174) for pain.
Brust A; Palant E; Croker DE; Colless B; Drinkwater R; Patterson B; Schroeder CI; Wilson D; Nielsen CK; Smith MT; Alewood D; Alewood PF; Lewis RJ
J Med Chem; 2009 Nov; 52(22):6991-7002. PubMed ID: 19860431
[TBL] [Abstract][Full Text] [Related]
3. Anti-allodynic efficacy of the chi-conopeptide, Xen2174, in rats with neuropathic pain.
Nielsen CK; Lewis RJ; Alewood D; Drinkwater R; Palant E; Patterson M; Yaksh TL; McCumber D; Smith MT
Pain; 2005 Nov; 118(1-2):112-24. PubMed ID: 16154696
[TBL] [Abstract][Full Text] [Related]
4. Solution structure of chi-conopeptide MrIA, a modulator of the human norepinephrine transporter.
Nilsson KP; Lovelace ES; Caesar CE; Tynngård N; Alewood PF; Johansson HM; Sharpe IA; Lewis RJ; Daly NL; Craik DJ
Biopolymers; 2005; 80(6):815-23. PubMed ID: 15931669
[TBL] [Abstract][Full Text] [Related]
5. 'Messy' Processing of χ-conotoxin MrIA Generates Homologues with Reduced hNET Potency.
Ziegman R; Brust A; Jha P; Cardoso FC; Lewis RJ; Alewood PF
Mar Drugs; 2019 Mar; 17(3):. PubMed ID: 30875751
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the norepinephrine transporter by the venom peptide chi-MrIA. Site of action, Na+ dependence, and structure-activity relationship.
Sharpe IA; Palant E; Schroeder CI; Kaye DM; Adams DJ; Alewood PF; Lewis RJ
J Biol Chem; 2003 Oct; 278(41):40317-23. PubMed ID: 12885787
[TBL] [Abstract][Full Text] [Related]
7. Conus venom peptide pharmacology.
Lewis RJ; Dutertre S; Vetter I; Christie MJ
Pharmacol Rev; 2012 Apr; 64(2):259-98. PubMed ID: 22407615
[TBL] [Abstract][Full Text] [Related]
8. Cyclic MrIA: a stable and potent cyclic conotoxin with a novel topological fold that targets the norepinephrine transporter.
Lovelace ES; Armishaw CJ; Colgrave ML; Wahlstrom ME; Alewood PF; Daly NL; Craik DJ
J Med Chem; 2006 Nov; 49(22):6561-8. PubMed ID: 17064074
[TBL] [Abstract][Full Text] [Related]
9. Two new classes of conopeptides inhibit the alpha1-adrenoceptor and noradrenaline transporter.
Sharpe IA; Gehrmann J; Loughnan ML; Thomas L; Adams DA; Atkins A; Palant E; Craik DJ; Adams DJ; Alewood PF; Lewis RJ
Nat Neurosci; 2001 Sep; 4(9):902-7. PubMed ID: 11528421
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the norepinephrine transporter by χ-conotoxin dendrimers.
Wan J; Brust A; Bhola RF; Jha P; Mobli M; Lewis RJ; Christie MJ; Alewood PF
J Pept Sci; 2016 May; 22(5):280-9. PubMed ID: 26910400
[TBL] [Abstract][Full Text] [Related]
11. Conotoxins: molecular and therapeutic targets.
Lewis RJ
Prog Mol Subcell Biol; 2009; 46():45-65. PubMed ID: 19184584
[TBL] [Abstract][Full Text] [Related]
12. The synthesis of SO-3, a conopeptide with high analgesic activity derived from Conus striatus.
Dai Q; Liu F; Zhou Y; Lu B; Yu F; Huang P
J Nat Prod; 2003 Sep; 66(9):1276-9. PubMed ID: 14510617
[TBL] [Abstract][Full Text] [Related]
13. Toxins 'R' Us: more pharmacological tools from nature's superstore.
Harvey AL
Trends Pharmacol Sci; 2002 May; 23(5):201-3. PubMed ID: 12007990
[TBL] [Abstract][Full Text] [Related]
14. chi-Conopeptide MrIA partially overlaps desipramine and cocaine binding sites on the human norepinephrine transporter.
Bryan-Lluka LJ; Bönisch H; Lewis RJ
J Biol Chem; 2003 Oct; 278(41):40324-9. PubMed ID: 12837768
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of cone snail venom peptides (conopeptides).
Vetter I; Lewis RJ
Curr Top Med Chem; 2012; 12(14):1546-52. PubMed ID: 22827523
[TBL] [Abstract][Full Text] [Related]
16. Chemical modification of conotoxins to improve stability and activity.
Craik DJ; Adams DJ
ACS Chem Biol; 2007 Jul; 2(7):457-68. PubMed ID: 17649970
[TBL] [Abstract][Full Text] [Related]
17. High-throughput synthesis of conopeptides: a safety-catch linker approach enabling disulfide formation in 96-well format.
Brust A; Tickle AE
J Pept Sci; 2007 Feb; 13(2):133-41. PubMed ID: 17160973
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of intrathecally administered Xen2174, a synthetic conopeptide with norepinephrine reuptake inhibitor and analgesic properties.
Okkerse P; Hay JL; Sitsen E; Dahan A; Klaassen E; Houghton W; Groeneveld GJ
Br J Clin Pharmacol; 2017 Apr; 83(4):751-763. PubMed ID: 27987228
[TBL] [Abstract][Full Text] [Related]
19. Cone snail venomics: from novel biology to novel therapeutics.
Prashanth JR; Brust A; Jin AH; Alewood PF; Dutertre S; Lewis RJ
Future Med Chem; 2014 Oct; 6(15):1659-75. PubMed ID: 25406006
[TBL] [Abstract][Full Text] [Related]
20. Conopeptide characterization and classifications: an analysis using ConoServer.
Kaas Q; Westermann JC; Craik DJ
Toxicon; 2010 Jul; 55(8):1491-509. PubMed ID: 20211197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
